ArticleCureus2021
Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings.
Kamal Sharma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
2021
this papercites it